Immunomodulatory imide drugs (IMiDs), which have FDA approval for treatment of multiple myeloma and myelodysplastic syndrome, degrade IKAROS and disrupt the expression of HOXA9 target genes without affecting HOXA9 expression itself. This evidence concerns the gene HOXA9 and myelodysplastic syndrome.